Shionogi – Discover Pharma

Welcome to Discover Pharma! Today is : September 22, 2026

Shionogi

Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
FDA approves Tivicay PD for children with HIV weighing at least 2kg
ViiV Healthcare has received US FDA approval for Tivicay PD [...]

September 4, 2026
Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics
Olorofim meets primary endpoint in phase 3 OASIS aspergillosis study
F2G and Shionogi have reported that oral olorofim met the [...]

June 18, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
China approves Symproic for opioid-induced constipation
China’s National Medical Products Administration has approved Shionogi’s Symproic for [...]

June 11, 2026
Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas
Shionogi and BioVersys agree €498M licensing deal for NTM drug candidates
Deal gives Shionogi access to BioVersys’ BV500 program targeting serious [...]

May 5, 2026
Clinical & Regulatory
Cefiderocol shows improved outcomes when used earlier in treatment pathway, new European data reveals
May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK